Actually I think it's more like $32m royalty to Biota using an...

Actually I think it's more like $32m royalty to Biota using an exchange rate of 2.07.

Check out the rest of GSK's announcement, they have obviously put a much bigger focus on promoting Relenza in seasonal markets as there is just no way that the stockpiling orders have made that.

This bodes REALLY well for the LANI ROW license... I wonder if GSK are going to bid for it as they are obviously focused on maintaining this revenue stream.

Wow, I still cannot believe how strong a quater this has been. A mild influenze season but yet we have had a whopping AUD460m sales in a single quarter.

Best of all we have seem comments that Canada will increase the weighting towards Relenza and even possible the USA. I'm glad I held through thick and thin.